Adaptive Biotechnologies (ADPT) Competitors

Adaptive Biotechnologies (NASDAQ:ADPT) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations, community ranking and profitability.

Does the media refer more to ADPT or GRFS?

In the previous week, Adaptive Biotechnologies had 5 more articles in the media than Grifols. MarketBeat recorded 9 mentions for Adaptive Biotechnologies and 4 mentions for Grifols. Adaptive Biotechnologies' average media sentiment score of 1.14 beat Grifols' score of 1.08 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, ADPT or GRFS?

Adaptive Biotechnologies has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Do insiders and institutionals believe in ADPT or GRFS?

99.2% of Adaptive Biotechnologies shares are held by institutional investors. 6.4% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has better valuation & earnings, ADPT or GRFS?

Grifols has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$189.53M	8.52	-$159.49M	-$0.96	-11.07
Grifols	$7.21B	0.85	$64.20M	$1.17	7.65

Do analysts prefer ADPT or GRFS?

Adaptive Biotechnologies currently has a consensus target price of $9.83, indicating a potential downside of 7.49%. Given Adaptive Biotechnologies' higher probable upside, research analysts clearly believe Adaptive Biotechnologies is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Grifols	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Does the MarketBeat Community favor ADPT or GRFS?

Grifols received 252 more outperform votes than Adaptive Biotechnologies when rated by MarketBeat users. However, 58.14% of users gave Adaptive Biotechnologies an outperform vote while only 56.23% of users gave Grifols an outperform vote.

Company	Underperform	Outperform
Adaptive Biotechnologies	Outperform Votes 100 58.14%	Underperform Votes 72 41.86%
Grifols	Outperform Votes 352 56.23%	Underperform Votes 274 43.77%

Is ADPT or GRFS more profitable?

Grifols has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -89.12%. Grifols' return on equity of 0.00% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-89.12%	-64.65%	-26.45%
Grifols	N/A	N/A	N/A

Summary

Grifols beats Adaptive Biotechnologies on 10 of the 19 factors compared between the two stocks.